Recent evidence indicates that the transactivation of estrogen receptor a (ERa) requires estrogen-dependent receptor ubiquitination and degradation. Here we show that estrogen-unbound (unliganded) ERa is also ubiquitinated and degraded through a ubiquitin-proteasome pathway. To investigate this ubiquitin-proteasome pathway, we purified the ubiquitin ligase complex for unliganded ERa and identified a protein complex containing the carboxyl terminus of Hsc70-interacting protein (CHIP). CHIP preferentially bound to misfolded ERa and ubiquitinated it to induce degradation. Ligand binding to the receptor induced the dissociation of CHIP from ERa. In CHIPÀ/À cells, the degradation of unliganded ERa was abrogated; however, estrogen-induced degradation was observed to the same extent as in CHIP þ / þ cells. Our findings suggest that ERa is regulated by two independent ubiquitin-proteasome pathways, which are switched by ligand binding to ERa. One pathway is necessary for the transactivation of the receptor and the other is involved in the quality control of the receptor.
Introduction
The effects of estrogen are mediated through the estrogen receptors ERa and ERb, which function as ligand-induced transcriptional factors and belong to the nuclear receptor superfamily Mangelsdorf et al, 1995; Chambon, 1996; McKenna and O'Malley, 2002) . Estrogen binding to its receptor induces the ligand-binding domain (LBD) to undergo a characteristic conformational change, whereupon the receptor dimerizes, binds to DNA and subsequently stimulates the gene expression. ERa is stimulated by two distinct activation regions, activation function-1 (AF-1) and AF-2, which are located in the C-terminal LBD and exert ligand-dependent transcriptional activity. Cellular response to estrogen is tightly controlled, and a large number of ERainteracting proteins have been described as coactivators or corepressors that modify ERa transcriptional activity (Shang et al, 2000; Yanagisawa et al, 2002; Metivier et al, 2003) .
Crystal-structural analysis of ERa and other nuclear receptors has revealed the presence of 12 conserved helices in their LBD (Shiau et al, 1998) . The LBD forms a structure described as a sandwich of 12 a-helices (Helices 1-12) with a central hydrophobic ligand-binding pocket. Helix 12, the most Cterminal of these helices, has been identified as the critical core (AD core) of the AF-2 function of the receptor and plays an important role in coactivator binding to the ligand-bound receptor. In the presence of the ligand, the hinge region between Helices 11 and 12 moves closer to Helices 3 and 5, and Helix 12 is positioned over the ligand-binding pocket formed by Helices 3-5. The repositioned Helix 12 forms a hydrophobic groove with Helices 3 and 5. This hydrophobic groove is known to be important for the interaction with LXXLL motifs found in coactivator molecules (Heery et al, 1997) .
The activation of nuclear receptors appears to be coupled with the degradation of these proteins by the ubiquitinproteasome pathway (Boudjelal et al, 2000; Dace et al, 2000; Blanquart et al, 2002) . Several recent studies have focused on the involvement of the ubiquitin-proteasome pathway in the estrogen-dependent degradation of ERa, which can be blocked with specific inhibitors of proteasome function, such as MG132 and lactacystin. It has also been reported that the 26S proteasome is essential for estrogendependent ERa transcription activity (Nawaz et al, 1999a; Lonard et al, 2000; Reid et al, 2003) . Furthermore, several components of the ubiquitin-proteasome pathway have been identified as nuclear receptor-interacting proteins, including SUG1/TRIP1 (Lee et al, 1995) , RSP5/RPF1 (Imhof and McDonnell, 1996) , E6-AP (Nawaz et al, 1999b) and UBC9 (Poukka et al, 1999) . These observations suggest that the ubiquitin-proteasome pathway may play an important role in regulating nuclear receptor levels and restricting the duration and magnitude of receptor activity in response to ligands. Nonetheless, mechanisms governing ERa protein levels remain poorly understood.
Here we show that, in the absence of estrogen, ERa is also ubiquitinated and degraded via a ubiquitin-proteasome pathway. The observation that estrogen-dependent ubiquitination of the receptor required the AD core region within the ERaLBD, whereas the ubiquitination of the unliganded receptor did not, raised the possibility that the ubiquitin ligase for unliganded ERa might differ from the ligase involved in estrogen-dependent ubiquitination. Therefore, we purified the ubiquitin-ligase complex for unliganded ERa and identified a chaperone complex containing the carboxyl terminus of Hsc70-interacting protein (CHIP) (Ballinger et al, 1999; Dai et al, 2003) . CHIP selectively bound to and ubiquitinated misfolded ERa and stimulated the degradation of these receptors. This model was further supported by an experiment using CHIP-deficient mouse (CHIPÀ/À) embryonic fibroblast cells. The unliganded ERa was degraded in CHIP þ / þ cells but not in CHIPÀ/À cells under thermally stressed conditions. In contrast, estrogen-dependent degradation was observed in both CHIP þ / þ and CHIPÀ/À cells, supporting the idea that the inactive and active forms of the receptor are regulated by two independent ubiquitin-proteasome pathways. Our findings shed light on the ubiquitinproteasome network regulating nuclear receptors.
Results
Unliganded ERa is degraded through a ubiquitin-proteasome pathway As shown in Figure 1A , addition of estrogen to MCF-7 cells reduced the level of ERa protein. The reduction of ERa was inhibited by the proteasome inhibitors MG132 or lactacystin. In the absence of estrogen, MG132 or lactacystin treatment also resulted in ERa accumulation ( Figure 1A , lanes 3 and 5), suggesting that not only estrogen-bound ERa but also unliganded ERa is degraded through proteasomes. In ubiquitination assay, ERa was ubiquitinated in both the presence and absence of estrogen ( Figure 1B , lanes 3 and 4), indicating that this process is mediated through ubiquitin-proteasome pathways.
We next determined whether the degradation of unliganded and liganded ERa is regulated by the same ubiquitin-proteasome pathway. It has been reported that truncated ERa, ERaDAD, which does not have an AD core domain, does not exhibit estrogen-dependent degradation (Lonard et al, 2000) . Thus, we examined the ubiquitination and degradation of ERaDAD. ERa and ERaDAD were transfected into 293 cells and the ERa protein level was examined by Western blot analysis. While the ERa degradation was observed regardless of estrogen treatment, ERaDAD was stabilized by ligand binding, as it accumulates in response to estrogen. MG132 treatment increases the levels of ERaDAD in the absence of the ligand but does not affect its estrogen-induced accumulation ( Figure 1C ). We next tested whether ERaDAD turnover is The MCF-7 cells were cultured in the presence or absence of estrogen (10 À8 M), or the proteasome inhibitor MG132 or lactacystin (10 À6 M). ERa level was analyzed by Western blotting using antiERa monoclonal antibody. (B) ERa was ubiquitinated in the absence of estrogen. MCF-7 cells were cultured in the presence or absence of estrogen (10 À8 M) or MG132 (10 À6 M). ERa was immunoprecipitated using anti-ERa antibody. The ubiquitination status of ERa was analyzed by Western blotting using anti-ubiquitin antibody. (C) ERaDAD was selectively degraded in the absence of estrogen. 293 cells were transfected with either ERa or ERaDAD (500 ng). At 24 h post-transfection, the cells were cultured in the presence or absence of estrogen (10 À8 M) or MG132 (10 À6 M). ERa or ERaDAD protein levels were analyzed by Western blotting using anti-ERa antibody. (D) ERaDAD was ubiquitinated in the absence of estrogen. Flag-tagged ERaDAD (500 ng) was transfected into 293 cells in the presence or absence of estrogen (10 À8 M) or MG132 (10 À6 M). Flag-tagged ERaDAD was immunoprecipitated using antiFlag M2 antibody. The ubiquitination status of ERaDAD was analyzed by Western blotting using anti-ubiquitin antibody. through ubiquitination. In the absence of MG132, we detected almost no or little ubiquitination of ERaDAD in the presence and absence of estrogen ( Figure 1D , lanes 2 and 4). However, in the presence of MG132, we observed smeary bands of ubiquitin-conjugated ERaDAD products in the absence of estrogen ( Figure 1D , lane 3). These results indicate that while ERaDAD shows no ligand-dependent ubiquitination, unliganded ERaDAD is still degraded through ubiquitinproteasome pathways. According to these results, there are possibly two independent ubiquitination pathways for ERa.
Unliganded ERa associates with a protein complex containing CHIP We then investigated the region responsible for the degradation of unliganded ERa. The protein level of truncated ERa was examined by Western blotting in the presence or absence of estrogen. As shown in Figure 2A , all of the deletion mutants containing the E domain accumulated with estrogen treatment. MG132 treatment increased the levels of these mutants, indicating that they were degraded through proteasome ( Figure 2A , lower panel). These results suggest that the region responsible for the degradation of unliganded ERa is located within ERaLBD. From these results, we speculated that an E3 ubiquitin ligase specifically binds and conjugates ubiquitin to the unliganded ERaLBD. We therefore attempted to identify the putative ubiquitin ligase for unliganded ERa. A HeLa cell extract-derived fraction was incubated with glutathione-S-transferase (GST)-fused ERaLBD in the presence or absence of estrogen. Proteins that interacted with ERaLBD were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and silver stained ( Figure 2B ). To identify the proteins that selectively bound to unliganded ERaLBD, we performed peptide mass fingerprinting, and revealed that the 35 kDa protein eluted from the unliganded ERaLBD column consisted of CHIP ( Figure 2B ). The result obtained from peptide mass fingerprinting was confirmed by Western blotting using a specific antibody against CHIP ( Figure 2B , lower panel).
CHIP is known to possess E3 ubiquitin-ligase activity mediated by its carboxy-terminal U-box domain and has the ability to bind to chaperones Hsp/Hsc70 by means of its tetratricopeptide repeat (TPR) domain (Scheufler et al, 2000; Connell et al, 2001; Imai et al, 2002) . Mass spectrometric analysis also identified chaperone proteins Hsp/Hsc70 ( Figure 2B ), indicating that CHIP binds unliganded ERaLBD as a protein complex containing Hsp/Hsc70. Thus, we examined the interaction between ERa and CHIP/Hsp/Hsc70 complex using a co-immunoprecipitation method. As shown in Figure 2C , CHIP is selectively co-immunoprecipitated with 485
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GST-ERαLBD Extracts prepared from HeLa S3 cells were incubated with immobilized GST-ERaLBD in the presence or absence of estrogen (10 À6 M). ERa-interacting proteins were eluted from the GST-ERaLBD column by N-lauroyl sarkosin and subjected to SDS-PAGE followed by silver staining. The fractions eluted from unliganded GST-ERaLBD column (lane 1) and liganded GST-ERaLBD column (lane 2) are shown. Proteins eluted from both columns were examined by mass spectrometry. *Hsc70. (C) Interaction between unliganded ERa and CHIP in vivo. MCF-7 cells were lysed and subjected to immunoprecipitation using either anti-CHIP or anti-ERa antibody in the presence or absence of indicated ligands (estrogen (10 À8 M); OHT: 4-hydroxytamoxifen (10 À6 M); ICI: ICI182,780 (10 À7 M)). The precipitates were Western blotted with antibodies for CHIP, ERa and Hsc70. MCF-7 whole-cell extract is shown in lane 1 (WCE).
unliganded ERa and Hsc70. Cell treatment with either 4-hydroxytamoxifen (OHT), a partial antagonist of ERa, or ICI182,780 (ICI), a pure antagonist of ERa, abrogated the binding between ERa and CHIP. CHIP was also detected in the immunoprecipitation performed with an anti-ERa antibody in the absence of ligands, confirming the interaction between ERa and CHIP in vivo. The same results were obtained in the human endometrial adenocarcinoma cell line Ishikawa (data not shown).
To better characterize and identify other components of the CHIP-Hsc70 complex, we generated HeLa cell lines stably expressing Flag-HA double-tagged CHIP. The protein complex containing CHIP was precipitated and separated by SDS-PAGE. Protein identification of the purified proteins by mass spectrometric analysis identified KIAA0678, Hsp90, Hsc70, Hsp70, Hsp40 and CHIP ( Figure 3A) . The protein components of the CHIP complex were confirmed by Western blotting using specific antibodies. Hsp90, Hsc70, Hsp70, Hsp40 and BAG-1 in the CHIP complex are shared with the chaperone components, whereas other chaperone components, Hip, Hop and p23, were undetectable by Western blot analysis ( Figure 3B ). To investigate whether this protein complex binds to unliganded ERa, Flag-tagged ERa expressed in 293 cells was immunoprecipitated using anti-Flag monoclonal antibody. As shown in Figure 3C , all of the components detected in the CHIP complex by Western blotting existed in the precipitant ( Figure 3C , left panel). Next, to investigate whether this protein complex has the same composition in physiological conditions, ERa was immunoprecipitated from MCF-7 cells using a specific antibody for ERa. In the absence of estrogen, the protein complex purified from MCF-7 contained the same components as the complex in 293 cells ( Figure 3C , right panel), suggesting that this protein complex exists in the physiological conditions.
CHIP ubiquitinates and degrades unliganded ERa
To test whether CHIP is involved in the ubiquitination and degradation of unliganded ERa, either ERa or ERaDAD was transfected into 293 cells with or without CHIP. Western blot analysis revealed that, in the absence of estrogen, the steadystate levels of ERa and ERaDAD were decreased when CHIP was expressed ( Figure 4A ; 293, lanes 3 and 5). In contrast, in the presence of estrogen, the expression of CHIP exhibited little or no effect on the protein level of ERa and ERaDAD ( Figure 4A ; 293, lanes 4 and 6). Endogenous ERa in MCF-7 cells was also decreased by CHIP expression ( Figure 4A ; MCF-7). Cell treatment with MG132 or lactacystin blocked CHIP-dependent ERa degradation, indicating that the degradation is mediated through proteasome pathways ( Figure 4A , lower panel). We further determined the CHIP function by developing MCF-7 cells in which endogenous CHIP expression was suppressed by the introduction of a small interfering RNA (siRNA) complementary to sequences present in the CHIP mRNA. The introduction of the siRNA vector into MCF-7 cells resulted in the suppression of CHIP mRNA (data not shown) and protein expression, and the accumulation of ERa protein ( Figure 4B ). In contrast, a control vector failed to alter the CHIP or ERa protein level. In addition, either OHT or ICI treatment abrogated CHIP-induced ERa degradation ( Figure 4C ). Considering the observation that OHT-or ICIbound ERa showed no interaction with CHIP, it is suggested that the degradation requires binding between ERa and CHIP.
To confirm that CHIP enhances unliganded ERa degradation, pulse-chase experiments were performed. In the absence of CHIP, the half-life of unliganded ERa exceeded 12 h ( Figure 4D ; 293), whereas, in the presence of CHIP, the turnover of unliganded ERa increased and exhibited a halflife of approximately 6 h ( Figure 4D ; 293). The half-life of estrogen-bound ERa was not changed by the expression of CHIP (data not shown). In MCF-7 cells, CHIP also enhanced the turnover of endogenous ERa in the absence of estrogen ( Figure 4D ; MCF-7). To test the specificity of this effect, we created constructs in which the TPR and U-box domains of CHIP were deleted (DTPR and DUbox). CHIP binds to Hsp/ Hsc70 by means of its TPR motif, while also displaying E3 ubiquitin-ligase activity mediated by its U-box domain. Although the expression of these proteins was similar to that of wild-type CHIP (data not shown), the deletion of either of these domains abolished the effects of CHIP on ERa or ERaDAD protein level ( Figure 5A ). The requirement of a TPR motif indicates that CHIP may need to interact with Hsc70 to promote ERa degradation. Functional requirement of the U-box implies that CHIP regulates ERa ubiquitination. In order to validate this model, we evaluated the presence of Hsp/Hsc70 and ERa in complexes containing CHIPDTPR or CHIPDUbox. As shown in Figure 5B , CHIPDTPR did not have the ability to form a complex with Hsc70 and ERa, indicating that Hsc70 mediates the interaction between ERa and CHIP. Finally, we tested whether CHIP enhances ERa turnover through ubiquitination. When ERa was coexpressed with CHIP, we observed the appearance of smeary bands of ubiquitin-conjugated ERa products ( Figure 5C , lanes 3 and 5). In the presence of estrogen, CHIP did not enhance the conjugation of ubiquitin to ERa ( Figure 5C, lanes 2 and 4) . Overall, these observations indicate that the ubiquitination and degradation of unliganded ERa is mediated by a protein complex containing CHIP ubiquitin ligase.
CHIP preferentially recognizes and degrades misfolded ERa
To investigate the effect of CHIP on the transcriptional activity of ERa, a luciferase assay was performed as shown in Figure 6A . While the protein level of ERa was reduced by the expression of CHIP ( Figure 6B, upper panel) , the transcriptional activity of ERa was slightly enhanced by CHIP expression ( Figure 6B , lower panel, compare lane 2 with lanes 5 and 8). Therefore, we next estimated the level of transcriptional activity per ERa protein amount. When ERa was coexpressed with CHIP, the level of transcriptional activity per ERa protein was about two-fold higher than ERa alone ( Figure 6B , lower panel, compare lane 3 with lanes 6 and 9).
Our results show that CHIP binds to unliganded but not to liganded ERa. In addition, CHIP was localized mainly in the cytoplasm ( Figure 6C ). From these observations, it is difficult to believe that CHIP acts as a coactivator for ERa in the nucleus. Furthermore, ERa(HE82), which has three aminoacid substitutions in the DNA-binding region (C domain) in ERa and has almost no ability to bind DNA (Mader et al, 1989) , was also degraded by CHIP, suggesting that the CHIPdependent degradation of ERa does not require DNA binding. From these results and previous reports Meacham et al, 2001; Murata et al, 2001; Goldberg, 2003) , we hypothesized that CHIP preferentially ubiquitinates misfolded ERa proteins to eliminate them. CHIP expression may selectively reduce the protein level of unfolded or misfolded ERa, which has less activity than the normal form. Consequently, CHIP could enhance the level of transcriptional activity per ERa protein.
To test this hypothesis, amino-acid substitutions were introduced into ERa to induce protein misfolding. In the absence of ligands, ERa(V364E) (McInerney et al, 1996) and ERa(C447A) (Reese and Katzenellenbogen, 1992) , both of which have an amino-acid substitution in the LBD and exhibit temperature sensitivity, were unstable and degraded faster than wild-type protein at a nonpermissive temperature (371C). Wild-type ERa also degraded to the same extent as temperature-sensitive mutants when cells were cultured under thermally stressed conditions (cells were cultured at 421C for 30 min) ( Figure 6D , upper panel, compare lane 1 with lanes 2, 3 and 6). In contrast, ERa(L540Q) (Ince et al, 1995) and ERaDAD, which have either an amino-acid substitution or truncation in the flexible Helix 12 region, exhibited the same stability as wild type at 371C ( Figure 6D , upper panel, compare lane 1 with lanes 4 and 5). Under a permissive temperature (301C), the protein stability of ERa(V364E) and ERa(C447A) was comparable with that of the wild type ( Figure 6D, lower panel) .
In a luciferase assay, these four mutated ERa proteins showed a loss or reduction of transcriptional activity compared to the wild type ( Figure 6E , lane 5), and they were able to suppress wild-type activity when coexpressed with wildtype ERa ( Figure 6E, lane 8) . CHIP did not enhance the ERa activity suppressed by ERa(L540Q) or ERaDAD; however, transcriptional activity suppressed by ERa(V364E) or ERa(C447A) was recovered by CHIP expression ( Figure 6E , lanes 9 and 10). These results suggest that CHIP may preferentially ubiquitinate ERa(V364E) and ERa(C447A) to degrade these mutants.
If CHIP is directly involved in the hydrolysis of abnormal or mutant forms of ERa, then it should be able to form specific complexes with mutated or misfolded ERa. ERa or mutated forms of ERa were immunoprecipitated from transfected cells and the presence of CHIP and chaperone proteins was detected using specific antibodies. At a permissive temperature (301C), the amount of CHIP in the precipitate pellets with ERa(V364E) or ERa(C447A) was almost the same in precipitates with the wild type ( Figure 7A, right panel) . However, at a nonpermissive temperature (371C), CHIP and BAG-1, a co-chaperone that binds to both Hsc70 and the proteasome, preferentially co-immunoprecipitated with ERa(V364E) and ERa(C447A), while the amount of other chaperone components in precipitants was unchanged ( Figure 7A, left panel) . In addition, thermally stressed conditions (421C for 30 min) also increased the CHIP and BAG-1 levels in the precipitated pellet ( Figure 7A , left panel, lane 6). Consistent with the results obtained from the degradation and interaction experiments, the polyubiquitination of the temperature-sensitive mutants or thermally denatured ERa was enhanced at nonpermissive temperature ( Figure 7B , compare left panel with right panel).
Liganded but not unliganded ERa degradation is observed in CHIPÀ/À cells
To firmly establish the importance of the observation of CHIPdependent ERa degradation, we isolated mouse embryonic fibroblast (MEF) cells from either CHIPÀ/À, CHIP þ /À mice or wild-type littermates, CHIP þ / þ , and determined the protein level of ERa. To induce misfolding of ERa protein, these cells were cultured under thermally stressed conditions. In the absence of estrogen, the thermally stress conditions reduced ERa levels in both CHIP þ / þ and CHIP þ /À cells but not in CHIPÀ/À cells ( Figure 8A, lanes 4-6) . MG132 induced the accumulation of ERa in CHIP þ / þ and CHIP þ / À cells, indicating that ERa was degraded through proteasome pathways in these cells. These observations provide further support for a model in which CHIP preferentially binds misfolded ERa proteins and degrades them to maintain the quality of ERa protein in cells. Co-immunoprecipitation experiments showed the existence of ERa/Hsc70/CHIP complex in CHIP þ / þ cells but not in CHIPÀ/À cells ( Figure 8B ). Furthermore, estrogen treatment induced ERa degradation in CHIPÀ/À cells to the same extent as in CHIP þ / þ cells ( Figure 8C ), suggesting that CHIP is not involved in estrogendependent degradation, and supporting the idea that there are two independent ubiquitin-proteasome pathways for ERa ( Figure 8D ).
Discussion
Estrogen receptor a is regulated by two independent ubiquitin-proteasome pathways Several studies have mentioned that the AD core region of ERa is essential not only for transactivation but also for estrogen-dependent ERa degradation (Lonard et al, 2000) . These reports are in good agreement with our result that ERaDAD, which has no AD core region, does not show estrogen-dependent degradation. Interestingly, however, MG132 had no effect on ligand-bound ERaDAD; the steadystate level of ERaDAD in the absence of estrogen is accumulated in the presence of MG132. These results indicate that unliganded ERaDAD is still degraded through proteasome pathways. According to these observations, it is possible that the degradation pathway for the unliganded receptor differs from that for liganded. ERaDAD might be able to recruit a Temperature-sensitive mutants of ERa degraded faster than wildtype ERa in the absence of ligands. ERa(V364E), ERa(C447A), both of which are temperature sensitive, and ERa(L540Q) were generated by amino-acid substitutions of wild-type ERa. Indicated ERa or ERa mutants (500 ng) were transfected into 293 cells in the presence or absence of estrogen (10 À8 M) and MG132 (10 À6 M) at 301C (permissive temperature; lower panel), 371C (normal/nonpermissive temperature; upper panel) or under thermally stressed conditions (421C for 30 min; upper panel). Protein levels of ERa or mutants were analyzed by Western blotting using anti-ERa antibody. (E) CHIP recovered the transcriptional activity of ERa suppressed by coexpression of ERa mutants. ERa (100 ng), ERE-TATALuc (100 ng) and pRSVbGAL (100 ng) were cotransfected into 293 cells with or without either ERa(V364E), ERa(C447A), ERa(L540Q), ERaDAD (100 ng) or CHIP (100 ng), and cell extracts were used in a luciferase assay. degradation machinery for the unliganded receptor but not for the liganded. Otherwise, there may be a change in the conformation of the receptor, which would protect the receptor from degradation. Reid et al (2003) also demonstrated that unliganded ERa is subject to proteasome-mediated turnover, which is mechanistically different from the turnover of liganded ERa.
Several lines of evidence indicate that estrogen, progesterone and glucocorticoid receptors (GRs) are degraded in the presence of their cognate ligands (Nawaz et al, 1999a; Wallace and Cidlowski, 2001) . However, this is contrasted with observations of androgen and vitamin D receptors, which are accumulated in the presence of their agonist αFlag ERα Figure 7 The misfolding of ERa induced the recruitment of CHIP and BAG-1 to the complex. (A) CHIP and BAG-1 preferentially recognized and bound misfolded ERa. Flag-tagged ERa, ERa(V364E) or ERa(C447A) (100 ng) was transfected into 293 cells. These cells were cultured with MG132 (10 À6 M) at 301C (permissive temperature; right panel), 371C (normal/nonpermissive temperature; left panel) or under thermally stressed conditions (421C for 30 min; left panel). Extracts prepared from these cells (lanes 3-6) or untransfected cells (Mock) were subjected to immunoprecipitation using anti-Flag M2 antibody and then Western blotted using antibodies as indicated. The whole-cell extract is shown in lane 1 (WCE). (B) The ubiquitination status of the temperature-sensitive mutants or heat-shocked ERa was enhanced. Flag-tagged ERa, ERa(V364E) or ERa(C447A) (500 ng) was transfected into 293 cells. These cells were cultured with MG132 (10 À6 M) at 301C (right panel), 371C (left panel) or under thermally stressed conditions (421C for 30 min; left panel). Extracts prepared from these cells (lanes 2-5) or untransfected cells (Mock) were subjected to immunoprecipitation using anti-Flag M2 antibody. The ubiquitination status of ERa and mutants was analyzed by Western blotting using anti-ubiquitin antibody. (Li et al, 1999) . From our results, these inconsistent observations might be explained by the balance between the two degradation pathways in the cells. When the degradation pathway for unliganded receptors is more active than that for liganded receptors, these receptors would stabilize in the presence of ligands. In contrast, when the liganded receptor degradation pathway is stronger than the unliganded receptor degradation pathway, the protein level of receptors is downregulated by ligand treatment.
CHIP containing a protein complex specifically binds and ubiquitinates unliganded estrogen receptor To address the mechanism of the ubiquitination and degradation of unliganded ERa, we purified proteins using GST-fused ERaLBD, and identified CHIP, which specifically bound to unliganded ERaLBD. Our findings indicate that CHIP binds unliganded ERa as a protein complex containing Hsp90, Hsc70, Hsp70, Hsp40 and BAG-1, all of which are known to possess or assist chaperoning functions, and a Dna J-like protein, KIAA0678. Dna J is a member of the Hsp40 family of molecular chaperones, which regulate the activity of Hsp70s. Dna J-like proteins that contain regions closely resembling a Dna J domain are suggested to regulate the activity of Dna J proteins during protein translocation, assembly and disassembly (Cheetham and Caplan, 1998) .
CHIP expression with ERa enhanced the conjugation of ubiquitin to the receptors and stimulated degradation. Receptor ubiquitination and degradation was abrogated when cells were treated with estrogen. These results are in good agreement with the results obtained from binding experiments. Furthermore, OHT and ICI, both of which inhibited the interaction between CHIP and ERa, reduced the CHIP-mediated degradation of ERa. These findings confirmed the idea that unliganded ERa ubiquitination is mediated by CHIP. In immunostaining, CHIP was largely detected in the cytoplasm ( Figure 6C ). The localization of CHIP was not changed when cells were cultured under heatstressed conditions (data not shown). According to these results, CHIP-dependent ERa ubiquitination may occur mainly in the cytoplasm. However, we cannot exclude the possibility that a small amount of CHIP is involved in the ubiquitination of ERa in the nucleus.
Recently, CHIP was reported to induce ubiquitination of the GR bound to Hsp90 for proteasomal degradation (Connell et al, 2001) . While our findings indicate that CHIP selectively binds to unliganded ERa and ubiquitinates it, CHIP-mediated GR degradation is observed in the presence of ligands. Recent reports indicate that in the presence of ligands, nuclear receptors do not remain permanently bound at a promoter, but rather undergo cycles of binding and unbinding (Shang et al, 2000; Stenoien et al, 2001; Galigniana et al, 2004) . The cycling of ligand-bound ERa requires proteasomal activity . Together with these reports and our observations, it is possible that the binding of estrogen to ERa induces the dissociation of CHIP and the association of other ubiquitin ligases, which are involved in receptor cycling at a promoter. The ligand-dependent cycling of GR is known to be much faster than that of ERa and both chaperones and proteasomes are thought to be important for GR cycling since the disruption of either leads to alterations in the exchange rate (Galigniana et al, 2004) . According to these results, it is possible that, while the chaperone complex containing CHIP mainly resides in the cytoplasm, it may translocate into the nucleus and regulate the cycling of liganded GR.
CHIP is involved in the quality control of estrogen receptor
Since CHIP selectively bound to and ubiquitinated unliganded ERa, CHIP seemed not to be directly involved in transcriptional regulation. Recently, it was shown that CHIP is involved in the ubiquitination of the immature cystic fibrosis transmembrane conductance regulator (CFTR) in the endoplasmic reticulum-associated degradation (ERAD) pathway (Wickner et al, 1999; Meacham et al, 2001 ). Based on these findings, it is speculated that CHIP may be a new category of E3 enzyme responsible for the quality control of cellular proteins linked to the function of molecular chaperones. However, there is no experimental evidence to show that CHIP indeed acts as E3 ubiquitin ligase capable of distinguishing the non-native states from native states of target proteins in vivo.
In this study, we have shown that temperature-sensitive mutants of ERa preferentially recruited CHIP to ubiquitinate and degrade these receptors under nonpermissive temperatures. In addition, the ubiquitination and degradation of unliganded ERa was enhanced when cells were cultured under thermally stressed conditions. These observations suggest that CHIP preferentially induces the hydrolysis of abnormal or mutant forms. Using MEF cells derived from CHIPÀ/À or wild-type littermates, we confirmed the importance of the observation of CHIP-mediated unfolded ERa degradation. These observations provide direct in vivo evidence that CHIP selectively ubiquitinated thermally denatured ERa. Our observations provide the first in vivo evidence that CHIP functions as 'quality-control E3' involved in the selective ubiquitination of target proteins by recognizing the non-native state in a molecular chaperone-assisted manner. Furthermore, estrogen treatment induced the degradation of ERa in CHIPÀ/À cells to the same extent as in CHIP þ / þ cells, suggesting that CHIP is not involved in estrogen-dependent degradation, and supporting the idea that there are two independent ubiquitin-proteasome pathways for ERa. Considering that nuclear receptors have conserved LBDs and that some are known to associate with a chaperone complex, our findings raise the possibility that other members of the nuclear receptor family may also be regulated by two independent ubiquitin-proteasome pathways.
Materials and methods

Expression vectors, antibodies, cell culture and transfection
These are available as Supplementary data at The EMBO Journal Online.
Co-immunoprecipitation and Western blotting 293 cells were transfected with the indicated plasmids, lysed in TNE (10 mM Tris-HCl (pH 7.8), 1% NP-40, 0.15 M NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mg/ml aprotinin) buffer. Extracted proteins were immunoprecipitated with the antibody-coated protein A/G Sepharose (Amersham) or anti-Flag M2 agarose (Sigma). The bound proteins were separated by SDS-PAGE, transferred onto polyvinylidine difluoride membranes (Millipore) and detected with indicated antibodies, and secondary antibodies conjugated with horseradish peroxidase. Specific proteins were detected using enhanced chemiluminescence (ECL) Western blot detection system (Amersham).
Ubiquitination assay MCF7 and 293 cells, which were transfected with or without Flagtagged ERa and HA-tagged CHIP, were lysed with radioimmunoprecipitation (RIPA) buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with COMPLETE protease inhibitor mixture (Roche) and kept for 20 min on ice. The extracts clarified by centrifugation were immunoprecipitated with anti-Flag agarose for 1 h at 41C. After washing the resin with RIPA buffer, the bound proteins were eluted by incubation for 1 h at 41C with Flag peptide in RIPA buffer (0.4 mg/ml). Immunoprecipitates were immunoblotted with the indicated antibody.
Protein purification
Immobilized GST-ERaLBD fusion proteins were preincubated for 1 h at 41C in GST-binding buffer (20 mM Tris-HCl (pH 7.9), 180 mM KCl, 0.2 mM EDTA, 0.5 mM PMSF, 1 mM DTT) containing BSA (1 mg/ml) with or without estrogen (10 À6 M). Bead-immobilized proteins were then incubated at 41C for 6-10 h with HeLa cell extracts in the presence or absence of 10 À6 M estrogen. After washing with GST buffer (GST-binding buffer with 0.1% NP-40) three times, the beads were further washed with GST buffer containing 0.2% N-lauroyl sarkosine. Proteins bound to ERa were eluted with 15 mM reduced glutathione in elution buffer (50 mM Tris-HCl (pH 8.3), 150 mM KCl, 0.5 mM EDTA, 0.5 mM PMSF, 5 mM NaF, 0.08% NP-40, 0.5 mg/ml BSA, 10% glycerol). For purification of the Flag/HA-CHIP complex, HeLa cells stably expressing Flag/ HA-CHIP were extracted with TNE buffer and extracted proteins were incubated with anti-Flag M2 agarose for 2 h at 41C. After washing the resin with TNE buffer, the bound proteins were eluted by incubation for 1 h at 41C with Flag peptide in TNE buffer (0.4 mg/ml). For further purification, eluted fractions were incubated with anti-HA agarose for 2 h at 41C. After washing with TNE buffer, the bound proteins were eluted with a small aliquot of HA peptide in TNE buffer (0.05 mg/ml).
Pulse chase MCF7 and 293 cells were transfected with or without ERa and CHIP, and 48 h post-transfection, the cells were labeled for 30 min at 371C with 50 mCi [ 35 S]methionine per ml in methionine-free Dulbecco's modified Eagle's medium (DMEM). The cells were then washed twice and incubated in DMEM containing 10% FBS for the indicated time periods (chase). At each time point of the chase, cell lysates were immunoprecipitated with anti-ERa antibody. The immunoprecipitates were resolved by SDS-PAGE and visualized by autoradiography. Phosphoimager was used to quantify the metabolically labeled ERa present at each time point.
Immunofluorescence
The 293 cells were grown on poly-L-lysine-coated eight-well chamber culture slides, and transfected with plasmids. At 24 h post-transfection, the cells were fixed with 4% paraformaldehyde in PBS for 10 min and permeabilized with Triton buffer (50 mM TrisHCl (pH 7.5), 0.5% Triton X-100, 150 mM NaCl, 2 mM EDTA) for 15 min. The cells in each well were blocked with PBS containing 1% BSA and 0.5% goat serum for 3 h at 371C. The cells were incubated with anti-HA and ERa antibody in PBS containing 1% BSA for 2 h at 371C. After washing with PBS, the cells were incubated with Alexa fluor 488 goat anti-rat IgG and Alexa fluor 594 goat anti-mouse IgG (Molecular Probes) for 1 h at 371C and washed with PBS. The sample was mounted in VECTASHIELD mounting medium (Vecter Labs) and analyzed with Leica TCS SP2 spectral confocal scanning system. RNAi MCF7 cells maintained in the DMEM medium containing charcoalstripped FBS were cotransfected with CHIP siRNA vector or luciferase siRNA vector (control) and pUC19 vector carrying puromycin-resistant gene. At 24 h post-transfection, the transfected cells were changed to the medium containing 1 mg/ml of puromycin. At 48 h after puromycin selection, the puromycin-resistant cells were harvested and lysed with TNE buffer. The equal amounts of extracted protein were subjected to Western blotting.
Supplementary data
Supplementary data are available at The EMBO Journal Online.
